Axa
CNST

Axa’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Axa’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-260,170
Closed -$6.08M – 1329
2021
Q1 		$6.08M Buy
260,170
+37,720
+17% +$1.14M 0.02% 656
2020
Q4 		$6.41M Buy
222,450
+32,754
+17% +$824K 0.02% 638
2020
Q3 		$3.84M Buy
189,696
+46,171
+32% +$1.13M 0.01% 697
2020
Q2 		$4.31M Buy
+143,525
New +$5.17M 0.02% 661

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa's CNST Position: Q2 2021 in Review

Axa sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 260,170 shares — an estimated $6.08M sold.

Axa first reported a position in CNST in Q2 2020 and held it in 4 quarters. The position peaked at $6.41M in Q4 2020. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Axa reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Axa sold 260,170 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $6.08M.
  • Axa first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2020 and held it in 4 quarters.
  • Axa's Constellation Pharmaceuticals, Inc. position peaked at $6.41M in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Axa's 13F filing for Q2 2021, filed 13 Aug 2021.